Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › exenatide

exenatide

10 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of exenatide

66 trials tracked of exenatide: 48 in phase 3 or 4 and 16 with published results. The most-cited published study has 568 citations.

66Trials tracked
48Phase 3 & 4
0Recruiting
16With published results
Phase distribution
Phase 4 24 Phase 3 24 Phase 2 7 Phase 1 2 Other / NA 9
  1. Phase 3 Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes Completed · 568 cited
  2. Phase 3 GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin Completed · 250 cited
  3. Phase 4 The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women Completed · 154 cited
  4. Phase 3 The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy Completed · 134 cited
  5. Phase 4 FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR) Completed · 133 cited
  6. Phase 4 Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes Completed · 108 cited
Show 44 more trials
  1. Phase 3 Role of Exenatide in NASH-a Pilot Study Completed · 107 cited
  2. Phase 4 Acute Effect of Exenatide on Brain Glucose Metabolism Completed · 95 cited
  3. Phase 4 Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes Completed · 83 cited
  4. Phase 3 Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period Completed · 80 cited
  5. Phase 3 Phase III Study to Evaluate Safety and Efficacy of Added Exenatide Versus Placebo to Titrated Basal Insulin Glargine in Inadequately Controlled Patients With Type II Diabetes Mellitus Completed · 77 cited
  6. Phase 4 Effect of Exenatide in Obese Patients With Accelerated Gastric Emptying Completed · 76 cited
  7. Phase 4 Weight Loss With Exenatide Treatment Completed · 23 cited
  8. Phase 4 Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria Completed · 10 cited
  9. Phase 4 Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults Completed · 8 cited
  10. Phase 4 Effects of Antidiabetic Medications on the Postprandial State in Prediabetes Completed · 4 cited
  11. Phase 4 Effect of Exenatide on Liver and Heart Fat and Inflammation Completed
  12. Phase 4 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed
  13. Phase 4 The Effect of Exenatide Compared to Lantus Insulin on Vascular Function in Type 2 Diabetes Completed
  14. Phase 4 Use of Exenatide and Pramlintide to Decrease Post-prandial Hyperglycemia Completed
  15. Phase 4 Intravenous Exenatide in Patients With Acute Brain Injury Completed
  16. Phase 4 Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia Completed
  17. Phase 4 New Onset Type 1 Diabetes: Role of Exenatide Completed
  18. Phase 4 Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM Completed
  19. Phase 4 How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics Completed
  20. Phase 4 Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients Completed
  21. Phase 4 Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione Completed
  22. Phase 4 The Vascular Effects of Exenatide Versus Metformin in Patients With Pre-Diabetes Completed
  23. Phase 4 Bioenergetic Alterations After Exenatide Administration Completed
  24. Phase 4 Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function Completed
  25. Phase 3 Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes Completed
  26. Phase 3 Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity Completed
  27. Phase 3 Effect on Weight Loss of Exenatide Versus Placebo Completed
  28. Phase 3 A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes Completed
  29. Phase 3 Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus Completed
  30. Phase 3 A Study Comparing Exenatide With Basal Insulin in Achieving a Target HbA1c With Minimum Weight Gain in Type 2 Diabetes Patients Completed
  31. Phase 3 Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1) Completed
  32. Phase 3 Exenatide Versus Glimepiride in Patients With Type 2 Diabetes Completed
  33. Phase 3 Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes Completed
  34. Phase 3 An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes Completed
  35. Phase 3 Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s) Completed
  36. Phase 3 Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes Completed
  37. Phase 3 Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin Completed
  38. Phase 3 An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus Completed
  39. Phase 3 Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin Completed
  40. Phase 3 A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes Completed
  41. Phase 3 A Study in Participants With Type 2 Diabetes Mellitus Completed
  42. Phase 3 Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin Completed
  43. Phase 2 A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients Completed
  44. Phase 2 Exenatide Once Weekly for Smoking Cessation Completed

Showing the 50 most-cited and recently-updated of 66 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
GLP-1 receptor agonists show greater weight loss in women than men across multiple trials
Nutrition & Obesity Medicine Meta-analysis
GLP-1 receptor agonists show greater weight loss in women than men across multiple trials Women Lose More Weight on GLP-1 Drugs Than Men Do
This systematic review and meta-analysis examined weight changes among adults with obesity, diabetes, or cardiovascular disease treated with…
• Women lose 11% weight versus 7% for men on these drugs • Helps adults using Wegovy Ozempic and similar weight loss medications • Works sam…
May 4, 2026
CPAP Most Effective for Apnea-Hypopnea Index, GLP-1 RAs Improve Weight in OSA
Diabetes & Endocrinology Meta-analysis
CPAP Most Effective for Apnea-Hypopnea Index, GLP-1 RAs Improve Weight in OSA CPAP and weight-loss drugs show different benefits for sleep apnea patients
This network meta-analysis of 3964 adults with obstructive sleep apnea found that CPAP produced the largest reduction in apnea-hypopnea inde…
A large analysis found CPAP best for breathing control, while weight-loss drugs improved body weight and blood sugar levels in sleep apnea p…
May 1, 2026
GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation rates
Psychiatry Meta-analysis
GLP-1RAs reduce weight and HbA1c in severe mental illness with low discontinuation rates New drugs help people with severe mental illness lose weight safely
This systematic review and meta-analysis evaluated glucagon-like peptide-1 receptor agonists in individuals with severe mental illness who h…
New weight loss drugs work well and stay safe for people with severe mental illness who struggle with obesity and high blood sugar.
May 1, 2026
Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease
Diabetes & Endocrinology Meta-analysis
Meta-analysis finds GLP-1RA plus SGLT2i reduces UACR in type 2 diabetes with kidney disease Combining two diabetes drugs protects kidneys better than using just one alone
This systematic review and meta-analysis of 1974 adults with type 2 diabetes and diabetic kidney disease found that combination therapy with…
Combining two common diabetes drugs offers better kidney protection than taking just one alone for people with type 2 diabetes
May 1, 2026
GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT
Cardiology RCT
GLP-1 receptor agonists associated with lower mortality in HFrEF on GDMT Heart Failure Patients Cut Death Risk With Common Diabetes Drug
In a retrospective, multicenter cohort study of 1,518 adults with HFrEF on guideline-directed therapy, GLP-1 receptor agonist use was associ…
Adding a common diabetes medication to standard heart failure treatment may significantly lower death rates.
medRxiv Apr 19, 2026
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes
Diabetes & Endocrinology Meta-analysis
Network meta-analysis of novel antidiabetic drugs in T2DM with CKD shows sotagliflozin, empagliflozin, and semaglutide rank highest for cardiovascular and renal outcomes A Clear Winner Emerges for Diabetes Patients with Kidney Disease
This network meta-analysis evaluated novel antidiabetic drugs, including SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors, i…
For millions managing both diabetes and kidney disease, new research clarifies which medications offer the best protection for their heart a…
Frontiers Apr 12, 2026
Narrative review assesses GLP-1 receptor agonists versus insulin for steroid-induced hyperglycemia and diabetes
Neurology Sys. Review
Narrative review assesses GLP-1 receptor agonists versus insulin for steroid-induced hyperglycemia and diabetes A Common Medication Side Effect May Have a Surprising New Solution
This narrative review evaluates the efficacy and safety of glucocorticosteroid-induced hyperglycemia (SIH) and steroid-induced diabetes (SID…
Doctors are exploring a new way to protect patients from the dangerous blood sugar spikes caused by essential steroid medications.
Frontiers Apr 12, 2026
Observational EHR study suggests GLP-1 RA may have lower risk than SGLT2i for HF outcomes
Cardiology
Observational EHR study suggests GLP-1 RA may have lower risk than SGLT2i for HF outcomes Observational study links GLP-1 RA to lower risk than SGLT2i in heart failure patients
An observational study using real-world EHR data from Stony Brook University Hospital compared GLP-1 RAs to SGLT2 inhibitors in patients wit…
In heart failure patients, GLP-1 receptor agonists showed a lower risk of death or hospitalization compared to SGLT2 inhibitors over one yea…
medRxiv Apr 9, 2026
GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight
Nutrition & Obesity Medicine Meta-analysis
GLP-1RAs reduce MACE risk in Asian and White adults with diabetes or overweight Do heart benefits from diabetes drugs work equally well across different races?
A meta-analysis of 74,703 adults with type 2 diabetes or overweight/obesity found GLP-1RAs reduced MACE risk versus placebo.
Diabetes drugs protect hearts in Asian and White adults, but the benefit for Black adults remains unclear due to small study numbers.
Apr 8, 2026
GLP-1 Receptor Agonist Use in Wolfram Syndrome Shows No Glycemic or BMI Benefit, Common GI Effects
Diabetes & Endocrinology Cohort
GLP-1 Receptor Agonist Use in Wolfram Syndrome Shows No Glycemic or BMI Benefit, Common GI Effects Can diabetes drugs help Wolfram syndrome? A new study looks at real-world use
A retrospective cohort study of 84 participants with genetically confirmed Wolfram syndrome and insulin-dependent diabetes found 35% had rec…
Doctors prescribed diabetes drugs to 35% of rare Wolfram syndrome patients, but records show no improvement in blood sugar, weight, or slowi…
medRxiv Apr 4, 2026